ASX:AGNPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals
Argenica Therapeutics Ltd
$0.150
Day Range
$0.150 – $0.155
52 Week Range
$0.087 – $0.770
Volume
0.00
Avg Volume (10D)
443.48K
Market Cap
$19.27M
Price Chart
Market Statistics
Open$0.150
Previous Close$0.150
Day High$0.155
Day Low$0.150
52 Week High$0.770
52 Week Low$0.087
Valuation
Market Cap19.27M
Shares Outstanding128.46M
Price to Book5.78
Trading Activity
Volume0.00
Value Traded0.00
Bid$0.150 × 30,482
Ask$0.160 × 96,500
Performance
1 Day6.90%
5 Day10.71%
13 Week-11.43%
52 Week-76.34%
YTD-47.46%
Technical Indicators
RSI (14)59.92
50-Day SMA$0.123
200-Day SMA$0.209
Latest News
Biotechnology
Argenica Therapeutics Reports ARG-007 Neuroprotection in Concussion Study
Argenica's ARG-007 delivers durable neuroprotection after repeat mild TBI in a concussion model, hinting at a disease-modifying therapy from a single dose.
Biotechnology
Argenica Therapeutics Establishes Expert Committee to Advance Phase 2b Stroke Trial
Argenica Therapeutics forms Clinical Advisory Committee to accelerate ARG-007 Phase 2b stroke trial.
Biotechnology
Argenica Study Confirms Compatibility of ARG-007 Candidate with Stroke Treatment Standard-of-Care Therapies
Argenica Therapeutics (ASX: AGN) has reported positive results from a drug-to-drug interaction assessment showing its lead candidate ARG-007 does not interfere with clot-dissolving agent tenecteplase in the treatment of acute ischemic stroke.
Biotechnology
Argenica Therapeutics Validates Efficacious ARG-007 Dose in New Pre-Clinical Stroke Study
Argenica Therapeutics (ASX: AGN) has released new data from an independent pre-clinical study validating the efficacy and dosing of lead neuroprotective peptide candidate ARG-007 for ischaemic stroke.